Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 145-154

  Markel, Gal ^a,b,d   Cohen Sinai, Tali ^a   Besser, Michal J ^a   Oved, Kfir ^e   Itzhaki, Orit ^a   Seidman, Rachel ^a   Treves, Avraham J ^a   Fridman, Eduard ^c   Keisari, Yona ^d   Dotan, Zohar ^c   Ramon, Jacob ^c   Schachter, Jacob ^a,c  

^a Sheba Cancer Research Center   (Israel)

^b Talpiot Medical Leadership Program   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Adoptive cell transfer; Immunotherapy; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CD4 CD8 RATIO; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LEUKOCYTE CULTURE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; CD4-CD8 RATIO; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; T-LYMPHOCYTES;

EID: 61449223099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics 2008. CA Cancer J Clin 58: 71-96, 2008.
2. National Institute of Health: SEER Cancer Statistics Review. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1990.
3. Golimbu M, Joshi P and Sperber A: Renal cell carcinoma: survival and prognostic factors. Urology 27: 291-301, 1986.
4. Bukowski RM and Novick AC: Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 64: SI1-SI44, 1997.
5. Coppin C, Le L, Porzsolt F and Wilt T: Targeted therapy for renal cell carcinoma. Cochrane Database Syst Rev 2: CD006017, 2008.
6. Sanchez-Ortiz RF, Tannir N, Ahrar K and Wood CG: Spontaneous regression of pulmonary metastases from renal cell carcinoma after radiofrequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170: 178-179, 2003.
7. Stoerkel S, Keymer R, Steinbach F and Thoenes W: Reaction patterns of tumor infiltrating lymphocytes in different renaLcell carcinomas and oncocytomas. Prog Clin Biol Res 378: 217-223, 1992.
8. Shabtai M, Ye H, Frischer Z, Martin J, Waltzer WC and Malinowski K: Increased expression of activation markers in renal cell carcinoma-infiltrating lymphocytes. J Urol 168: 2216-2219, 2002.
9. Bukur J, Malenica B, Huber C and Seliger B: Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 64: 1081-1092, 2003.
10. Zhang J, Chen Y, Li J, Zhang R, Wu Y, Zou L, Zhao T, Zhang X, Han J, Chen A and Wu Y: Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J Nephrol 19: 429-438, 2006.
11. Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T and Finke JH: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T-cells. J Clin Invest 104: 769-776, 1999.
12. Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, Das T, Zhang R, Chahlavi A, Tannenbaum CS, Novick A, Bukowski R and Finke JH: GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 66: 6816-6825, 2006.
13. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, Juhlin C and Kiessling R: Lack of interleukin-2 (IL-2) expression and selective expression of IL-IO mRNA in human renal cell carcinoma. Int J Cancer 63: 366-371, 1995.
14. Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I and Dimopoulos C: Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32: 317-322, 2004.
15. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC and Kwon ED: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101: 17174-17179, 2004.
16. Frankenberger B, Noessner E and Schendel DJ: Immune suppression in renal cell carcinoma. Sem Cancer Biol 17: 330-343, 2007.
17. Parton M, Gore M and Eisen T: Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24: 5584-5592, 2006.
18. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM and Rosenberg S: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 113: 293-301, 2008.
19. Gold PJ, Thompson JA and Markowitz DR: Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am 3: S85-S91, 1997.
20. Beignon AS, Skoberne M and Bhardwaj N: Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 4: 939-941, 2003.
21. + T-cells and is overcome by IL-2. Eur J Immunol 32: 634-643, 2002.
22. Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T and Schendel DJ: Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 11: 1733-1742, 2005.
23. Bleumer I, Oosterwijk E, De Mulder P and Mulders PF: Immunotherapy for renal cell carcinoma. Eur Urol 44: 65-75, 2003.
24. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE and Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
25. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
26. Rosenberg SA and Dudley M: Cancer regression in patients with metastatic melanoma after transfer of autologous antitumor lymphoccytes. Proc Natl Acad Sci 101: 14639-14645, 2004.
27. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M and Eberlein TJ: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13: 1939-1949, 1995.
28. + tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17: 2521-2529, 1999.
29. Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B and Schachter J: Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center. Isr Med Assoc J 8: 164-168, 2006.
30. Dudley ME, Wunderlich JR, Shelton TE, Even J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342, 2003.
31. + T-cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 150: 114-123, 1993.
32. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, Nagler A and Schachter J: Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE spectra apheresis machine. J Immunother 31: 563-568, 2008.
33. Markel G, Seidman R, Stern N , Cohen-Sinai T, Itzhaki O, Katz G, Treves A, Besser M, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A and Schachter J: Inhibition of human tumor-infiltrating lymphocytes (TIL) effector functions by homophilic carcinoembryonic cell adhesion molecule 1 (CEACAM1) interactions. J Immunol 177: 6062-6071, 2006.
34. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L and Mandelboim O: CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 168: 2803-2810, 2002.
35. Zbar B, Brauch H, Talmadge C and Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (Lond.) 327: 721-724, 1987.
36. Bubeník J: MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 25: 487-491, 2004.
37. + T-cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176: 7726-7735, 2006.
38. Effros RB and Pawelec G: Replicative senescence of T-cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18: 450-454, 1997.
39. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA and Hodes RJ: Persistence of tumor-infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 30: 123-129, 2007.
40. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B and Ceuppens JL: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 109: 501-509, 1997.
41. Thomson CW, Lee BP and Zhang L: Double-negative regulatory T-cells: non-conventional regulators. Immunol Res 35: 163-178, 2006.
42. Mattijssen V, Van Moorselaar J, De Mulder PH, Schalkwijk L and Ruiter DJ: Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to Interferon therapy, J Immunother 12: 64-69, 1992.
43. Ohmore T, Okada K, Arita N, Watanabe Y, Miyazako T and Tabei R: Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol Histopathol 10: 789-794, 1995.
44. Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J and Zimmermann W: The tumour suppressor gene CEACAM1 is completely but reversibly down-regulated in renal cell carcinoma. J Pathol 204: 258-267, 2004.
45. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, Yagel S and Mandelboim O: Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions: implications for congenital CMV infection. J Clin Invest 110: 943-953, 2002.
46. Morales VM, Christ A, Watt SM, Kim HS, Johnson KW, Utku N, Texieira AM, Mizoguchi A, Mizoguchi E, Russell GJ, Russell SE, Bhan AK, Freeman GJ and Blumberg RS: Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 163: 1363-1370, 1999.
47. + T lymphocytes. Nat Immunol 3: 229-236, 2002.
48. Moretta L and Moretta A: Killer immunoglobulin-like receptors. Curr Opin Immunol 16: 626-633, 2004.
49. Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmüller G and Nößner E: Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 75: 400-413, 1997.